Breaking News
June Raine
About June Raine
June qualified in medicine at Oxford University, and undertook postgraduate research leading to an MSc in pharmacology. After general medical posts and Membership of the Royal Colleges of Physicians (MRCP), she joined the then Medicines Division in 1985, and has worked in several licensing areas including the Review of Medicines, new drugs and abridged. Prior to becoming Chief Executive, June was Director of Vigilance and Risk Management of Medicines from 1999 to 2019.
As Chief Executive, June chairs the Executive Committee, which is the highest decision-making body in the agency.
NHS Fast Tracks New ‘Gamechanging’ Drug for Lung Cancer
March 21 2022
A targeted new drug for a rare and aggressive form of lung cancer will be […]
Evusheld Approved to Prevent COVID-19 in People Whose Immune Response is Poor
March 18 2022
A new medicine, Evusheld (tixagevimab/cilgavimab), has today been authorised for COVID-19 prevention by the Medicines […]
MHRA Approves Xevudy (sotrovimab), a COVID-19 Treatment Found to Cut Hospitalisation and Death by 79%
December 3 2021
Another COVID-19 treatment, Xevudy (sotrovimab), has today been approved by the Medicines and Healthcare products […]
First Oral Antiviral for COVID-19, Lagevrio (molnupiravir), Approved by MHRA
November 4 2021
The antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalisation and […]
MHRA Puts Delivering for Patients at the Heart of its Delivery Plan 2021-2023
July 5 2021
A new and ambitious Delivery Plan centred on putting patients first, has been published today […]
The MHRA Concludes Positive Safety Profile for Pfizer/BioNTech Vaccine in 12- to 15-year-olds
June 4 2021
An extension to the current UK approval of the Pfizer/BioNTech COVID-19 vaccine that allows its […]
UK Medicines Regulator Issues its First Authorisation Under Project Orbis
May 7 2021
A post-surgery treatment for lung cancer will be the first to receive an authorisation from […]